个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Sun, Juxian[1] * ; Guo, Rongping[2] ; Bi, Xinyu[3] ; Wu, Mengchao[1] ; Tang, Zhaoyou[4,5] ; Lau, Wan Yee[1,6] ; Zheng, Shusen[7] ; Wang, Xuehao[8] ; Yu, Jinming[9] ; Chen, Xiaoping[10] ; Fan, Jia[4,5] ; Dong, Jiahong[11] ; Chen, Yongjun[12] ; Cui, Yunfu[13] ; Dai, Chaoliu[14] ; Fang, Chihua[15] ; Feng, Shuang[16] ; Ji, Zhili[17] ; Jia, Weidong[18] ; Jia, Ningyang[19] ; Li, Gong[20] ; Li, Jing[21] ; Li, Qiu[22] ; Li, Jiangtao[23] ; Liang, Tingbo[24] ; Liu, Lianxin[18] ; Lu, Shichun[25] ; Lv, Yi[26] ; Mao, Yilei[27] ; Meng, Yan[16] ; Meng, Zhiqiang[28] ; Shen, Feng[29] ; Shi, Jie[1] ; Sun, Huichuan[30,31] ; Tao, Kaishan[32] ; Teng, Gaojun[33] ; Wan, Xuying[34] ; Wen, Tianfu[35] ; Wu, Liqun[36] ; Xia, Jinglin[37] ; Ying, Mingang[38] ; Zhai, Jian[39] ; Zhang, Leida[40] ; Zhang, Xuewen[41] ; Zhang, Zhiwei[42] ; Zhao, Haiping[43] ; Zheng, Donghai[44] ; Zhi, Xuting[45] ; Zhou, Jie[46] ; Zhou, Cuncai[47] ; Zhou, Jian[4,5] ; Zeng, Zhaochong[48] ; Zhu, Kangshun[49] ; Chen, Minshan[2] ; Cai, Jianqiang[3] ; Cheng, Shuqun[1] ;
单位： [1]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China [2]Sun Yat Sen Univ Canc Ctr, Dept Hepatobiliary Surg, Guangzhou, Peoples R China [3]Chinese Acad Med Sci, Canc Hosp, Dept Hepatobiliary Surg, Beijing, Peoples R China [4]Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China [5]Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Shanghai, Peoples R China [6]Chinese Univ Hong Kong, Fac Med, Shatin, Hong Kong, Peoples R China [7]Shulan Hangzhou Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China [8]Nanjing Med Univ, Affiliated Hosp 1, Hepatobiliary Ctr, Nanjing, Peoples R China [9]Weifang Med Univ, Clin Coll, Dept Oncol, Weifang, Peoples R China [10]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China [11]Tsinghua Univ, Beijing Tsinghua Chang Gung Hosp BTCH, Sch Clin Med, Dept Hepatobiliary & Pancreas Surg, Beijing, Peoples R China [12]Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Hepatobiliary Surg, Sch Med, Shanghai, Peoples R China [13]Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China [14]China Med Univ, Affiliated Shengjing Hosp, Dept Hepatobiliary & Spleenary Surg, Shenyang, Peoples R China [15]First Mil Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China [16]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Radiat Oncol, Shanghai, Peoples R China [17]Capital Med Univ, Beijing Anzhen Hosp, Dept Gen Surg, Beijing, Peoples R China [18]Univ Sci & Technol China, Affiliated Hosp 1, Dept Gen Surg, USTC, Hefei, Peoples R China [19]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Radiol, Shanghai, Peoples R China [20]Tsinghua Univ, Beijing Tsinghua Changgung Hosp BTCH, Sch Clin Med, Dept Radiat Oncol, Beijing, Peoples R China [21]Third Mil Med Univ, Xinqiao Hosp, Dept Hepatobiliary Surg, Chongqing, Peoples R China [22]Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Peoples R China [23]Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China [24]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China [25]Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Hepatobiliary Surg, Beijing, Peoples R China [26]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Peoples R China [27]PUMC & Chinese Acad Med Sci, Peking Union Med Coll PUMC Hosp, Dept Liver Surg, Beijing, Peoples R China [28]Fudan Univ Shanghai, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China [29]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, Shanghai, Peoples R China [30]Fudan Univ, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China [31]Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China [32]Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Peoples R China [33]Southeast Univ, Zhongda Hosp, Med Sch, Dept Radiol, Nanjing, Peoples R China [34]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Integrated Tradit Chinese & Western Med, Shanghai, Peoples R China [35]Sichuan Univ, West China Hosp, Dept Liver Surg, Chengdu, Peoples R China [36]Qingdao Univ, Affiliated Hosp, Div Hepatobiliary Pancreat Surg, Qingdao, Peoples R China [37]Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China [38]Fujian Med Univ Teaching Hosp, Fujian Prov Canc Hosp, Dept Abdominal Surg, Fuzhou, Peoples R China [39]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Intervent Radiol, Shanghai, Peoples R China [40]Third Mil Med Univ, Southwest Hosp, Dept Hepatobiliary Surg Inst, Chongqing, Peoples R China [41]Second Hosp Jilin Univ, MDept Hepatobiliary & Pancreas Surg, Changchun, Peoples R China [42]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Surg, Wuhan, Peoples R China [43]Inner Mongolia Med Univ, Dept Hepatobiliary & Pancreas Surg, Affiliated Hosp, Hohhot, Peoples R China [44]Beijing Weida Tradit Chinese Med Tumor Hosp, Dept Tradit Chinese Med, Beijing, Peoples R China [45]Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China [46]Southern Med Univ, Nanfang Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China [47]Jiangxi Prov Canc Hosp, Dept Hepatobiliary Surg, Nanchang, Jiangxi, Peoples R China [48]Fudan Univ, Zhongshan Hosp, Dept Radiat Oncol, Shanghai, Peoples R China [49]Guangzhou Med Univ, Dept Minimally Invas Intervent Radiol, Affiliated Hosp 2, Guangzhou, Peoples R China
出处：
DOI： 10.1159/000523997
ISSN：

关键词： Hepatocellular carcinoma Portal vein tumor thrombus Multidisciplinary therapy Guideline

摘要：
Portal vein tumor thrombus (PVTT) is very common and it plays a major role in the prognosis and clinical staging of hepatocellular carcinoma (HCC). We have published the first version of the guideline in 2016 and revised in 2018. Over the past several years, many new evidences for the treatment of PVTT become available, especially for the advent of new targeted drugs and immune checkpoint inhibitors which have further improved the prognosis of PVTT. So, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment. Future treatment strategies for HCC with PVTT in China would depend on new evidences from more future clinical trials. (C) 2022 The Author(s). Published by S. Karger AG, Basel

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学 2 区 胃肠肝病学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学 2 区 肿瘤学
JCR分区：
出版当年[2020]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Sun Juxian,Guo Rongping,Bi Xinyu,et al.Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)[J].LIVER CANCER.2022,11(4):315-328.doi:10.1159/000523997.
APA：
Sun, Juxian,Guo, Rongping,Bi, Xinyu,Wu, Mengchao,Tang, Zhaoyou...&Cheng, Shuqun.(2022).Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).LIVER CANCER,11,(4)
MLA：
Sun, Juxian,et al."Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)".LIVER CANCER 11..4(2022):315-328

相关文献

[1]The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus [2]Hepatocellular Carcinoma With Tumor Thrombus Occupying the Right Atrium and Portal Vein A Case Report and Literature Review [3]Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study [4]Long-term outcomes of deceased donor liver transplantation in hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study. [5]Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus [6]Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus [7]肝癌合并门静脉癌栓的手术治疗 [8]多梳基因Bmi-1在肝癌组织和门静脉癌栓组织中的表达及意义 [9]大肝癌伴门静脉癌栓病人综合疗法选择对照研究 [10]A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

资源点击量：426 今日访问量：2 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）